

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of</p> <p>Robert A. Lazarus et al.</p> <p>Serial No.: 10/005,306</p> <p>Filed: 7 NOVEMBER 2001</p> <p>For: HUMAN DNASE I HYPERACTIVE VARIANTS</p>	<p>Group Art Unit: 1652</p> <p>Examiner: NOT KNOWN</p> <hr/> <p><b>CERTIFICATE OF MAILING</b></p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>May 17, 2002</p> <p><i>Aida Guiam</i></p> <p>Aida Guiam</p>
--	--

TRANSMITTAL LETTER

BOX SEQUENCES

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

1. Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Paper copy of the Sequence Listing;
3. Certificate re Sequence Listing and diskette; and
4. Limited Recognition Under 37 CFR § 10.9(b).

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH INC.

Date: May 17, 2002

By:

David W. Evans

Reg. No. \*

Telephone No. (650) 225-1739



09157

PATENT TRADEMARK OFFICE

\* A copy of a document pursuant to 37 CFR § 10.9(b) is attached as proof of the authorization of the above to prosecute the referenced application. The original of this document is on file in the Office of Enrollment and Discipline.


BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATES PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

David Evans is hereby given limited recognition, *nunc pro tunc* from June 21, 2001, under 37 CFR § 10.9(b) as an employee of Genentech, Inc. to prepare and prosecute patent applications in which Genentech, Inc. is the assignee of record of the entire interest. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) David Evans ceases to lawfully reside in the United States, (ii) David Evans's employment with Genentech, Inc. ceases or is terminated, or (iii) David Evans ceases to remain or reside in the United States on an H1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: June 21, 2002



Harry I. Moatz  
Director of Enrollment and Discipline



## UNITED STATES PATENT AND TRADEMARK OFFICE


 COMMISSIONER OF PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, DC 20503

APPLICATION NUMBER	FILING DATE	INVENTOR NAME	CLASS
10 005,306	11/07/2001	Robert A. Lazarus	P104201

 09157  
 GENENTECH, INC  
 1 DNA WAY  
 SOUTH SAN FRANCISCO, CA 94080


CONFIRMATION NO. 6780

## FORMALITIES LETTER



Date Mailed: 03/20/2002

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990) and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-4202

PART 2 - COPY TO BE RETURNED WITH RESPONSE